Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730312 · ClinicalTrials.gov registry record · Phase 1
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT02730312 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 120 participants.
The verdict
NCT02730312, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Interventions
- BIOLOGICAL XmAb14045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730312
The ClinicalTrials.gov registry entry for NCT02730312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XmAb14045 is the first listed.
NCT02730312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730312 about?
NCT02730312 is a clinical study titled "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies". The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
What is the current status of trial NCT02730312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2016-08. Estimated completion is 2021-09.
What interventions are being tested in trial NCT02730312?
The interventions under investigation include: XmAb14045 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02730312?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.